Turn Therapeutics Inc. TTRX
requires, for purposes of this section, the terms "we," "us," or "the Company" or "Turn Therapeutics"
refer to Turn Therapeutics Inc.
non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Our lead program, GX-03, is being studied for moderate-to-severe
eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| R&D | $265.6K | $246.0K | — |
| SG&A | $5.6M | $1.6M | — |
| Total operating expenses | $5.9M | $1.8M | — |
| Operating income | -$5.9M | -$1.8M | — |
| Net income | -$3.2M | -$1.8M | — |
| EPS, basic | -0.12 | -0.07 | — |
| EPS, diluted | -0.12 | -0.07 | — |
| Shares, diluted (wtd. avg.) | $27.7M | $26.6M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash and equivalents | $4.0M | $498.3K | $1.2M |
| Total current assets | $5.2M | $1.1M | — |
| Other intangibles | $922.2K | $821.9K | — |
| Total assets | $12.2M | $2.0M | — |
| Total current liabilities | $6.0M | $707.9K | — |
| Total liabilities | $7.5M | $2.2M | — |
| Retained earnings | -$22.4M | -$19.2M | — |
| Total equity | $4.7M | -$177.4K | $85.8K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating cash flow | -$2.6M | -$1.4M | — |
| Stock-based compensation | $419.2K | $352.8K | — |
| Investing cash flow | -$153.0K | -$99.5K | — |
| Financing cash flow | $6.9M | $1.2M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-037505.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |